

## Immature Teratoma and Teratoma Associated with Associated with Malignancies, Clinicopathological and Survival Outcome at AHPGIC

Smruti Sudha Pattnaik<sup>1</sup>, Janmejaya Mohapatra<sup>2</sup>, Jita Parija<sup>3</sup>, Rekha Das<sup>3</sup>, Lalatendu Sarangi<sup>4</sup>, Bhagyaxmi Nayak<sup>2</sup>, Drman-  
oranjan Mohapatra<sup>5</sup>, Niranjan Rout<sup>6</sup>, Ashok Padhi<sup>5</sup>, Sagarika Samantray<sup>7</sup>, Niharika Panda<sup>8</sup>, Sanjukta Padhi<sup>9</sup>, Surendra  
Natha Senpathi<sup>10</sup>, Bharati Mishra<sup>11</sup>, Lalmoham Soy<sup>2</sup>, Tushar Kar<sup>12</sup>, Drlucy Das<sup>12</sup>, Richikhandelwal<sup>13</sup>, Agniv Sarkar<sup>13</sup> and  
Roma Rattan<sup>14</sup>

<sup>1</sup>Senior Resident, Department of gynaecology oncology AHPGIC, Cuttack, Utkal university, India

<sup>2</sup>Associate professor, Department of gynaecology oncology AHPGIC, Cuttack, Utkal university, India

<sup>3</sup>Professor, HOD, Department of gynaecology oncology AHPGIC, Cuttack, Utkal university, India

<sup>4</sup>Director of AHPGIC, cuttack, Utkal university, India

<sup>5</sup>Assistant professor, Department of gynaecology oncology AHPGIC, Cuttack, Utkal university, India

<sup>6</sup>Ex Professor, Department of pathology AHPGIC, cuttack, Utkal university, India

<sup>7</sup>Professor, HOD, Department of pathology, AHPGIC, Utkal university, India

<sup>8</sup>Professor, HOD, Radiation oncology, AHPGIC, Utkal university, India

<sup>9</sup>Associate professor, Department of medical oncology, AHPGIC, Utkal university, India

<sup>10</sup>Professor, Radiation oncology, Department radiation oncology, AHPIC, Cuttack, India

<sup>11</sup>Professor, HOD, Department of O & G, MKCG, India

<sup>12</sup>Professor, HOD, Department of O & G, SCBMCH, Utkal university, India

<sup>13</sup>Resident, Department of gynaecology oncology AHPGIC, Cuttack, Utkal university, India

<sup>14</sup>Associate professor, Department of Biochemistry, SCBMCH, India

\*Corresponding author: Smruti Sudha Pattnaik, Senior Resident, Department of gynaecology oncology AHPGIC, Cuttack, Utkal university, India, Tel: +918328953390, E-mail: drsmrutisudhapattnaik@gmail.com

Received Date: September 06, 2021 Accepted Date: October 06, 2021 Published Date: October 08, 2021

Citation: Smruti Sudha Pattnaik (2021) Immature Teratoma and Teratoma Associated with Associated with Malignancies, Clinicopathological and Survival Outcome at AHPGIC. JJ Oncol Clin Res 2: 1-19.

## Abstract

**Aim:** To analyse the clinicopathological features and the survival outcome of the nine cases of teratoma and immature teratoma associated with malignancies and immature teratoma alone.

**Material Methods:** The Case Included

1. HPS Confirmed Immature teratoma and teratoma with Malignancies After Staging Laparotomy
2. HPS Confirmed Cases of Immature Teratoma

Statistical Method of Analysis - Chi square test and Kaplan meyer survival analysis.

**Results:** The overall survival of immature teratoma is 66.7% with 95% confidence interval (.706, 1.000). The total survival in case of immature teratoma with associated is ther maignancies 66.7% with CI (.300, 1.000). In other hand the total survival in case of immature teratoma with other malignancies is 33.3% with CI (.0673, 1.000). This variability in the two groups of immature teratoma associated with malignancies is probably due two type of asscciated malignancies i.e embryonal and yolk sac and melanoma. The cases teratoma with squamos cell carcinoma all survived. Chi-square test on histology, shows there is no significant difference of survival pattern between different histology types at 5% level of significance. The total survival in case of low grade is 85.7% with CI (.633, 1.000). The total survival in case of high grade is 0.01%; which means there are very low survival in case of high-grade carcinoma. The total survival in case of Conservative surgery is 50% with CI (.225, 1.000); which means there are almost 50% survival in case of Conservative surgery. There is no death event happened in case of Radical surgery so survival cannot be estimated in such case. Thus, there is no significant difference of survival pattern between different treatment types at 5% level of significance ( $p= 0.2$ ).

## Introduction

An immature teratoma is a teratoma that contains anaplastic immature elements, and is often synonymous with malignant teratoma [1]. A teratoma is a tumor of germ cell origin, containing tissues from more than one germ cell line. An immature teratoma is a very rare tumor, representing 1% of all teratomas, 1% of all ovarian cancer, and 35.6% of all malignant ovarian germ cell tumors. It displays a specific age of incidence, usually in the first two decades, rare after menopause. A teratoma contains immature elements unlike a mature teratoma, which contains mature elements.

Totipotent neoplastic cells can differentiate along the embryonal or extraembryonal lines.

- The embryonal somatic differentiation along a primitive embryonic cell line results in embryonal carcinoma.
- Extra embryonal differentiation along the trophoblastic line gives rise to choriocarcinoma.
- The yolk sac line gives rise to yolk sac tumor (endodermal sinus tumor).

Immature teratoma on ultrasound appears nonspecific, whereas on CT and MRI predominantly solid with fat-filled elements. These patients with immature teratomas are surgically staged via exploratory laparotomy with cytologic washings, peritoneal biopsies, an omental assessment (either biopsy or omentectomy) [3]. Laparoscopy is the preferred mode in immature teratoma as an immature teratoma contains varying compositions of adult and embryonic tissues. The most common component identified is the neuroectoderm [4].

Tumors may also present embryonic components such as immature cartilage and skeletal muscle of mesodermal origin [5]. Immature teratoma is composed of embryonic endodermal derivatives [6].

Recently, a reliable biomarker, Oct-4, is helpful in diagnosing malignant immature teratomas [7].

Thurlberg and Schully devised a grading system on the basis of differentiation of the cellular element of the tumor. The proportion of immature tissue elements defines the grade of ma-

turity. This was later modified by Norris et al, who added a quantitative aspect to the degree of immaturity.

Grade 1 and 2 usually have a normal karyotype, whereas Grade 3 has an abnormal karyotype. But, there may be still detectable alterations in gene level. Treatment depends on fertility and grade. Since the occurrence of immature teratoma is rarely bilateral, the current standard of care is unilateral salpingo-oophorectomy with sampling of peritoneal implants [9]. Total abdominal hysterectomy with bilateral salpingo-oophorectomy are not indicated as they do not influence the outcome [10].

Fertility-sparing surgery is the form of treatment in young patients. Zhao et al reported that there are no significant differences in survival rates or post-operative fertility outcomes between the two.

## Aims and Objective of The Study

The aim of the study is to analyze the clinicopathological and survival outcome in 10 cases of immature and mature teratoma associated with malignancies.



## Material Methods

The case included-

1. HPS confirmed immature teratoma and mature teratoma with malignancies after staging laparotomy.
2. HPS confirmed cases of teratoma.


## Statistical Method of Analysis

Chi square test and Kaplan-Meier survival analysis.



PRIMITIVE  
CELL, ROUND  
IN SHAPE

IMMATURE TERATOMA EMBRYONAL CARCINOMA WITH NEUROEPITHELIUM



SCHILLER DUVAL  
BODIES



YOLK SAC COMPONENT

Figure 1: An Immature Teratoma with Neuroepithelium, Yolk sac and Embryonal Carcinoma

**Descriptive Statistics** – Total no of cases taken for analysis is 10. immature teratoma alone 3(30%), immature teratoma with malignancies 3(30%) and teratoma with malignancies 4(40%). Table 1 immature teratoma associated with malignancies were one

with yolk sac component, one with melanoma and one with embryonal carcinoma





	Frequency	Percent	Valid Percent	Cumulative Percent
immature teratoma	3	30.0	30.0	30.0
immature teratoma with other malignancies	3	30.0	30.0	60.0
teratoma with squamous cell carcinoma	4	40.0	40.0	100.0
<b>Total</b>	<b>10</b>	<b>100.0</b>	<b>100.0</b>	

Age and followup interval Table 2

	N	Minimum	Maximum	Mean	Std. Deviation
age	10	12.00	60.00	34.7000	17.08833
Follow up time (in months)	10	12.00	60.00	46.8000	18.28661
Valid N (listwise)	10				

An Immature Teratoma with Neuroepithelium, Yolksac and Embronal Carcinoma

The median age is 34 years with a minimum twelve and maximum 60 years Table 2. The follow up was a upto 60 months, minimum was 12 months. allthe the three cases f malignancies were followed up.

The case with a endodermal component presented the second year and the one with embryonal component in the 3<sup>rd</sup> year and the one with melanomain the first year.

The markers considered were ldh, bhcg,. Ldh was >400IU in 8(80%) and less <400IU in 2(20%) table 3.beta HC-G<1Miu in 3(30%), beta hcg>1Miu(70%) table 4. The low grade

7 (70%) cases and high grade 3(30%) table 5 The treatment was basically two groups. Conservative surgery group i.e unilateral-salpingoophorectomy 7(70%), radical surgery group i.e b/l salpingoophorectomy 3(30%) table 6. There were 8 (80%) in stage 1a and one in stageIII (10%)table7 and one in stage 1c2(10%). The cases of immature teratma associated with ther malignancies i.e embryonal, yolk sac cmpnent and melanoma received adjuvant ct 6 cycles. Whereas the four teratoma with squamous cell carcinomas and those with immature teratomas alone i.e 4 cases without adjuvant were followed up.

The case with immature teratma associated with embryonal carcinoma presented in stageIII, The ther two cases of immature teratoma associated with endormal sinus and that with maelanma presented instage ic2 and stage1a respectively. The four cases teratoma with squamos cell carcinoma presented in stage 1a.and the three cases imaatue teratoma alne presented in stage 1a

	Frequency	Percent	Valid Percent	Cumulative Percent
<400	2	20.0	20.0	20.0
Valid >400	8	80.0	80.0	100.0
Total	10	100.0	100.0	

**Table 3-LDH**

	Frequency	Percent	Valid Percent	Cumulative Percent
<1	3	30.0	30.0	30.0
Valid >1	7	70.0	70.0	100.0
Total	10	100.0	100.0	

**Table 4- BETA\_HCG**

	Frequency	Percent	Valid Percent	Cumulative Percent
Low	7	70.0	70.0	70.0
Valid High	3	30.0	30.0	100.0
Total	10	100.0	100.0	

**Table 5:** All the three cases of immature teratma with malignancies presented in higher grade. The other cases of immature teratoma and teratma associated with squamous cell carcinoma presented in lower grade

	Frequency	Percent	Valid Percent	Cumulative Percent
Conservative surgery	6	60.0	60.0	60.0
Valid radical surgery	4	40.0	40.0	100.0
Total	10	100.0	100.0	

**Treatment Table 6**

	Frequency	Percent	Valid Percent	Cumulative Percent
Valid stage 1a	8	80.0	80.0	80.0
stage III	1	10.0	10.0	90.0
stage 1c2	1	10.0	10.0	100.0
Total	10	100.0	100.0	

Stage Table 7

## Treatment \* Histology Crosstabulation

		Histology			Total
		immature teratoma	immature teratoma with other malignancies	teratoma with squamous cell carcinoma	
treatment	Conservative surgery	3	3	0	6
	radical surgery	0	0	4	4
Total		3	3	4	10

Table 8- Count

## Chi-Square Tests

	Value	df	P- value
Pearson Chi-Square	10.000 <sup>a</sup>	2	.007
Likelihood Ratio	13.460	2	.001
N of Valid Cases	10		

a. 6 cells (100.0%) have expected count less than 5. The minimum expected count is 1.20.

**Grade \* Histology Crosstabulation**

		Histology			Total
		immature teratoma	immature teratoma with other malignancies	teratoma with squamous cell carcinoma	
Grade	Low	3	1	3	7
	High	0	2	1	3
Total		3	3	4	10

Table 9- Count

**Chi-Square Tests**

	Value	df	<u>Asymp. Sig. (2- sided)</u>
Pearson Chi-Square	3.254 <sup>a</sup>	2	.197
Likelihood Ratio	3.900	2	.142
N of Valid Cases	10		

a. 6 cells (100.0%) have expected count less than 5. The minimum expected count is .90.

**stage \* Histology Crosstabulation**

		Histology			Total
		immature teratoma	immature teratoma with other malignancies	teratoma with squamous cell carcinoma	
Stage	stage 1a	2	2	4	8
	stage III	0	1	0	1
	stage 1c2	1	0	0	1
Total		3	3	4	10



## Chi-Square Tests

	Value	df	<u>Asymp. Sig. (2-sided)</u>
Pearson Chi-Square	5.000 <sup>a</sup>	4	.287
Likelihood Ratio	5.142	4	.273
N of Valid Cases	10		

a. 9 cells (100.0%) have expected count less than 5. The minimum expected count is .30.

## LDH \* Histology Crosstabulation

	Histology			Total
	immature teratoma	immature teratoma with other malignancies	teratoma with squamous cell carcinoma	
LDH <400	1	0	1	2
LDH >400	2	3	3	8
Total	3	3	4	10

## Chi-Square Tests

	Value	df	<u>Asymp. Sig. (2-sided)</u>
Pearson Chi-Square	1.146 <sup>a</sup>	2	.564
Likelihood Ratio	1.690	2	.429
N of Valid Cases	10		

a. 6 cells (100.0%) have expected count less than 5. The minimum expected count is .60.

**BETA\_HCG \* Histology Crosstabulation**

		Histology			Total
		immature teratoma	immature teratoma with other malignancies	teratoma with squamous cell carcinoma	
BETA_HCG	<1	2	1	0	3
	>1	1	2	4	7
Total		3	3	4	10

**Chi-Square Tests**

	Value	df	Asymp. Sig. (2- sided)
Pearson Chi-Square	3.651 <sup>a</sup>	2	.161
Likelihood Ratio	4.579	2	.101
N of Valid Cases	10		

a. 6 cells (100.0%) have expected count less than 5. The minimum expected count is .90.

**Status \* Histology Crosstabulation**

		Histology			Total
		immature teratoma	immature teratoma with other malignancies	teratoma with squamous cell carcinoma	
Status	Survive	2	1	4	7
	Death	1	2	0	3
Total		3	3	4	10

**Chi-Square Tests**

	Value	df	Asymp. Sig. (2- sided)
Pearson Chi-Square	3.651 <sup>a</sup>	2	.161
Likelihood Ratio	4.579	2	.101
N of Valid Cases	10		

**Table 13** : a. 6 cells (100.0%) have expected count less than 5. The minimum expected count is .90.

Cross tabulation analysis done of the individual factors i.e grade, stage, markers (ldh.bhcg),type of surgery ,with histology using the pearson chiquare and likehod ratio. Each factor analysed with three histological groups i.e immature teratma, immature

teratoma with malignanciesand teratoma with malignancies the only significant assciation was that f type f suregery with the three grups with a p value-.007.

**Survival analysis**


**Overall Survival Analysis**

time	n.risk	n.event	survival	std.err	lower 95% CI	upper 95% CI
24	9	1	0.889	0.105	0.706	1
36	8	2	0.667	0.157	0.420	1

Here it can be observed that the overall survival is 66.7% with 95% confidence interval (.706, 1.000)

**Overall Survival Plot**

Table 14



**Figure 2:** Over all aurvival Probability

**Descriptive Statistics (Histology)**

Histology	n	events	median	0.95LCL	0.95UCL
immature teratoma	3	1	NA	36	NA
immature teratoma with other malignancies	3	2	36	24	NA
teratoma with squamous cell carcinoma	4	0	NA	NA	NA

Table 15

**HistologyThree category Survival Analysis**


Histology Type	Time (in months)	n.risk	n.event	survival	std.err	lower 95% CI	upper 95% CI
immature teratoma	36	3	1	0.667	0.272	0.300	1.000
immature teratoma with other malignancies	24	3	1	0.667	0.272	0.2995	1.000
	36	2	1	0.333	0.272	0.0673	1.000
teratoma with squamous cell carcinoma	NA	NA	NA	NA	NA	NA	NA

The total survival in case of immature teratoma is 66.7% with CI (.300, 1.000). In other hand the total survival in case of immature teratoma with other malignancies is 33.3% with CI (.0673, 1.000)

Overall survival of immature teratoma is 66.7% with 95% confidence interval (.706, 1.000). The immature teratoma associated with malignancies are divided into two categories the total survival in case of immature teratoma with associated is their malignancies 66.7% with CI (.300, 1.000) total survival in case of


immature teratoma with other malignancies is 33.3% with CI (.0673, 1.000). The cases teratoma associated with squamous cell carcinoma had no disease recurrence and all the 4 cases had survived

### **Histology Three category Survival Plot**



**Figure 3:** Overall survival analysis of the three groups i.e immature teratoma(imt), teratoma with malignancies(twm), immature teratoma with malignancies(imtwm)

### **Grade (two category) Survival Plot**



From the above plot it can be said there are high survival in case of low grade and low survival in case of high grade.

**Figure 4:** Grade Survival Plot




**Chi-square test on Grade**

grade	N	Observed (O)	Expected (E)	(O-E) <sup>2</sup> /E	(O-E) <sup>2</sup> /N
Low	7	1	2.528	0.923	6.48
High	3	2	0.472	4.943	6.48

N.B.:  $\chi^2 = 6.5$  on 1 degrees of freedom,  $p = 0.01$

Table 17

**Grade (two category) Survival Plot**

From the above plot it can be said there are high survival in case of low grade and low survival in case of high grade.

**Chi-square test on Grade**

grade	N	Observed (O)	Expected (E)	(O-E) <sup>2</sup> /E	(O-E) <sup>2</sup> /N
Low	7	1	2.528	0.923	6.48
High	3	2	0.472	4.943	6.48

N.B.:  $\chi^2 = 6.5$  on 1 degrees of freedom,  $p = 0.01$

**Descriptive Statistics (Treatment)**

Treatment	n	events	median	0.95LCL	0.95UCL
Conservative surgery	6	3	36	36	NA
Radical surgery	4	0	NA	NA	NA

Among total 10 cases, there are 6 cases with Conservative surgery and 4 cases with Radical surgery. 3 deaths can be observed in the Conservative surgery category whereas in Radical surgery there is no death case.

**Treatment (Two category) Survival Analysis**

Treatment	Time (in months)	n.risk	n.event	survival	std.err	lower 95% CI	upper 95% CI
Conservative surgery	24	6	1	0.833	0.152	0.583	1.000
	36	5	2	0.500	0.204	0.225	1.000
Radical surgery	NA	NA	NA	NA	NA	NA	NA

The total survival in case of Conservative surgery is 50% with CI (.225, 1.000); which means there are almost 50% survival in case of Conservative surgery. There is no death event happened in case of Radical surgery so survival cannot be estimated in such .case


**Chi-square test on Treatment**

Treatment	N	Observed (O)	Expected (E)	(O-E) <sup>2</sup> /E	(O-E) <sup>2</sup> /V
Conservative Surgery	6	3	1.92	0.612	1.88
Radical Surgery	4	0	1.08	1.083	1.88

N.B.:  $\chi^2 = 1.9$  on 1 degrees of freedom,  $p = 0.2$

Thus, there is no significant difference of survival pattern between different treatment types at 5% level of significance ( $p = 0.2$ ).

### Treatment (two category) Survival Plot



From the above plot it can be said there are high survival in case of Radical surgery and low survival in case of Conservative surgery.

## Results

Here it can be observed that the overall survival of immature teratoma is 66.7% with 95% confidence interval (.706, 1.000). The total survival in case of immature teratoma with associated is their malignancies 66.7% with CI (.300, 1.000). In other hand the total survival in case of immature teratoma with other malignancies is 33.3% with CI (.0673, 1.000). this variability in the two groups of immature teratoma associated with malignancies is probably due two type of associated malignancies i.e embryonal and yolk sac and melanoma. The cases teratoma with squamos cell carcinoma all survived. Chi-square test on histology, shows there is no significant difference of survival pattern between different histology types at 5% level of significance. Among total 10 cases, there are 7 cases with low grade and 3 cases with high grade carcinoma. One death can be observed in the low-grade category where as in high grade category there are 2 death cases. The total survival in case of low grade is 85.7% with CI (.633, 1.000). The total survival in case of high grade is 0.01%; which means there are very low survival in case of high grade carcinoma. Among total 10 cases, there are 6 cases with Conservative surgery and

4 cases with Radical surgery. 3 deaths can be observed in the Conservative surgery category where as in Radical surgery there is no death case. The total survival in case of Conservative surgery is 50% with CI (.225, 1.000); which means there are almost 50% survival in case of Conservative surgery. There is no death event happened in case of Radical surgery so survival cannot be estimated in such case. From the above survival plot it can be said there are high survival in case of Radical surgery and low survival in case of Conservative surgery. Thus, there is no significant difference of survival pattern between different treatment types at 5% level of significance ( $p= 0.2$ ).

## Conclusion

The median age of presentation was 34 yrs although the lowest age being 12yrs to uppermost age 60 yrs. Maximum nos case of immature teratoma were low grade and early stage. The immature teratoma associated with malignancies were higher grade. The conservative approach was preferred in early stage and low grade. The overall survival of immature teratoma is better than overall survival of immature teratoma with malignancies. The type of

associated malignancies i.e yolk sac and embryonal component can differently affect the survival. Teratoma with squamous cell carcinoma has a good survival in early stage The low-grade type has better survival. The radical surgery group shows a better outcome.

The rarity of such cases, and early age of presentation prompted us to analyse their clinicopathological and survival factors. So, that it could be of help to others in deciding the radicality of management on the basis of the above factors.

---

## References

1. Sun H, Ding H, Wang J, Zhang E, Fang Y, et al. (2019) The Differences Between Gonadal and Extra-Gonadal Malignant Teratomas In Both Genders And The Effects Of Chemotherapy. *Bmc Cancer*. 19: 408.
2. Nci Dictionary of Cancer Terms (2011) National Cancer Institute.
3. Damjanov I (2009) *Pathology Secrets* (3rd Edn) Philadelphia, Pa: Mosby/Elsevier.
4. Jump Up To:<sup>A B C</sup> Ulbright Tm (2004) Gonadal Teratomas: A Review And Speculation". *Advances In Anatomic Pathology*. 11: 10–23.
5. Schmidt D, Kommos F (2007) Teratoma of The Ovary. Clinical And Pathological Differences Between Mature and Immature Teratomas]. *Der Pathologe(In German)* 28: 203–8.
6. Alwazzan Ab, Popowich S, Dean E, Robinson C, Lotocki R, (2015) Pure Immature Teratoma of The Ovary in Adults: Thirty-Year Experience of a Single Tertiary Care Center". *International Journal of Gynecological Cancer*. 25: 1616–22.
7. Coran Ag, Adzick Ns (2012) *Pediatric Surgery* (7th Ed.). Philadelphia, Pa: Elsevier Mosby. 539–48.
8. Jump Up To:<sup>A B C D E F G</sup> Di Saia Pj, Creasman Wt (2012) *Clinical Gynecologic Oncology*(8th Edn). Philadelphia, Pa: Elsevier/Saunders: 329–56.
9. Ki Ey, Byun Sw, Choi Yj, Lee Kh, Park Js (2013) Clinicopathologic Review of Ovarian Masses in Korean Premenarchal Girls". *Int J Med Sci* 10: 1061-7.
10. Jump Up To:<sup>A B</sup> Malkasian Gd, Symmonds Re, Dockerty Mb (1965) Malignant Ovarina Teratomas. Report Of 31 Cases". *Obstetrics And Gynecology* 25: 810-4.



**Submit your manuscript to a JScholar journal and benefit from:**

- ¶ Convenient online submission
- ¶ Rigorous peer review
- ¶ Immediate publication on acceptance
- ¶ Open access: articles freely available online
- ¶ High visibility within the field
- ¶ Better discount for your subsequent articles

Submit your manuscript at  
<http://www.jscholaronline.org/submit-manuscript.php>